Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

The antitumor efficiency and clinical translation of traditional nanomedicines is mainly
restricted by low drug loading, complex preparation technology, and potential toxicity …

Importance Patients with locally advanced pancreatic cancer have historically poor
outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Chemotherapy is an important part of multimodality pancreatic cancer treatment. After
curative resection, adjuvant chemotherapy can significantly improve disease free survival …

Photodynamic therapy (PDT) with selectivity and security has been widely acknowledged as
a promising therapeutic option for cancer treatment. With the swift blossom of phototherapy …

Background Initial recurrence mapping of resected pancreatic ductal adenocarcinoma
(PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up …

At the time of diagnosis, only about 20% of patients with pancreatic ductal adenocarcinoma
(PDAC) have resectable disease. PDAC treatment necessitates a multidisciplinary …

Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-
related deaths across the world. A lack of durable responses to standard-of-care …